What is the role of thrombopoietin receptor agonists in the treatment of immune thrombocytopenic purpura (ITP)?

Updated: Apr 22, 2018
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

In 2008, two thrombopoietin receptor agonists, romiplostin (Nplate) and eltrombopag (Promacta), became available for patients with chronic ITP. In August 2015, the U.S. Food and Drug Administration expanded the indication for eltrombopag to include treatment of chronic ITP in patients 1 year of age and older who have not achieved an appropriate response with other medical therapy or splenectomy. [58]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!